Immunome To Present Poster Highlighting Preclinical Evaluation Of IM-1021, A ROR1-Targeted Antibody Drug Conjugate, At The 36th EORTC-NCI-AACR Symposium
Portfolio Pulse from Benzinga Newsdesk
Immunome, Inc. (NASDAQ:IMNM) will present a poster on the preclinical evaluation of its ROR1-targeted antibody drug conjugate, IM-1021, at the 36th EORTC-NCI-AACR Symposium in Barcelona on October 24, 2024.
October 18, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunome is set to present preclinical data on its ROR1-targeted ADC, IM-1021, at a major cancer symposium, potentially increasing interest in its cancer therapies.
The presentation of preclinical data at a major symposium can increase visibility and interest in Immunome's cancer therapies, potentially leading to positive sentiment and a short-term stock price increase.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90